Marksans Pharma is a pioneer in the pharmaceutical industry thanks to its customer-first approach. Marksans has made a name for itself in competitive regulatory markets by focusing on both prescription and over-the-counter medications. Indian pharmaceutical company Marksans Pharma Limited As its primary activity, it is involved in the production and distribution of pharmaceutical formulations for research.
Marksans Pharma Share Price Target 2024-2030
Marksans Pharma ltd is a company that has been listed on stock exchanges and focuses primarily on its core business. The company’s performance on the stock exchange has been improving, which has led to an increase in the share price as well. This is due to the company’s reputation—the goodwill it has gained over time. The company’s performance in the pharmaceutical industry and the trust that customers place in it when purchasing various medicines contribute to its goodwill.
Marksans Pharma Share Price Target Today Update
Marksans Pharma Ltd. can be a profitable investment choice if you’re looking for stocks with a high return. At 2024-08-21, the Marksans Pharma Ltd. quote is equivalent to 220.900 INR. The “Marksans Pharma Ltd” stock price outlook for 2029-08-17 is 374.382 Indian Rupees, and our projections indicate a long-term increase. The revenue is expected to be around +69.48% after a five-year investment. In 2029, your current $100 investment could reach $169.48.
Read More:-
Marksans Pharma Business Profile
Marksans Pharma is a manufacturer of pharmaceutical formulations. It is most interested in over-the-counter and prescription drugs, which are widely used in a wide range of applications like treating cancer, stomach infections, diabetes, inflammations, heart problems, and painkillers, among other things.
- Product Portfolio: The business has more than one thousand five hundred stocking units and more than three hundred products in various formulations, including plain, enteric-coated, and film-coated tablets, hard and soft gelatin capsules, oral liquids or ointments, and gelatin capsules.
- Acquisition & Capex: Marksans acquired Teva’s manufacturing unit in April 2023 with the intention of increasing its capacity by 200 crores of rupees in total capital expenditure. The company was already working on preacquisition of Rs. 160 crores for FY24, which included Rs. 78 crores in acquisition costs for Capex FY23, which totaled approximately 53 crores.
- New Approval: The Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC) received FDA approval on October 23. The Nexium 24 HR Delayed Release Capsules, in the words of AstraZeneca Pharmaceuticals LP, are bioidentical. The new medication will be manufactured in Goa.
Operation
- USA – Co bought Time Cap Labs Inc. in June 2015. The region is served by this specific WoS. Over 50 items are included on the list of their Private Label OTC and Generic Prescription Drug product lines. Target, Walmart, Walgreens, and Kroger, among others, have customers.
- UK and Europe- Relonchem and Bells Healthcare, both owned by The Co., provide services to the region. In the United Kingdom, the majority of private label and branded cough liquids come from Bells Healthcare, the largest manufacturer, while Relonchem offers a wide range of own-label healthcare pharmaceutical products. The company has formed partnerships with prominent UK retailers such as Tesco, Asda, Morrisons, Coop, and Boots, resulting in increased distribution and market penetration.
- Australia and New Zealand – Marksans Pharma collaborates with Woolworths Ltd., Coles Mayer Ltd., Aldis, Metcash, and Fauldings, as well as with Teva and Arrow Pharma through a partnership for the New Zealand pharmaceutical market.
New Products List
- USA – 32 products are in the pipeline, 20 are oral solids, 12 are ointments and creams, 4 are Softgels.
- UK – Planned 34 new filings in next 3 yrs. + 16 products awaiting approval.
- Australia and New Zealand – 10 products are in the pipeline and expected to be launched over the next 2 yrs.
- ROW – 124 products approved, 120 awaiting, approval & 108 in the pipeline.
Subsidiaries
- Marksans Holdings Ltd (UK) – WOS
2. Marksans Pharma Inc (US) – WOS
3. Nova Pharmaceuticals Australasia Pty Ltd. (Australia) – 60% stake
4. Access Healthcare for Medical Products LLC (UAE) – WOS
Marksans Pharma Fundamentals & Quarterly Results
| Market Cap | ₹ 7,509 Cr. |
| Current Price | ₹ 166 |
| High / Low | ₹ 186 / 70.2 |
| Stock P/E | 23.7 |
| Book Value | ₹ 41.4 |
| Dividend Yield | 0.30 % |
| ROCE | 22.2 % |
| ROE | 18.6 % |
| Face Value | ₹ 1.00 |
| Debt to equity | 0.06 |
| Debt Capacity | 0.14 |
| Debt preceding year | ₹ 111 Cr. |
| Debt | ₹ 111 Cr. |
| Reserves | ₹ 1,830 Cr. |
| EPS | ₹ 7.00 |
| EPS last year | ₹ 5.88 |
| Pledged percentage | 0.00 % |
| FCF Prev Ann | ₹ 53.0 Cr. |
| EVEBITDA | 13.8 |
| Industry PE | 27.0 |
| PEG Ratio | 0.46 |
| Piotroski score | 7.00 |
| Earnings yield | 6.30 % |
| Sales growth 5Years | 15.2 % |
Read More:-
Marksans Pharma Quarterly Results
| Metric | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
| Sales | 358 | 330 | 349 | 361 | 363 | 418 | 434 | 453 | 480 | 486 | 500 | 531 | 586 |
| Expenses | 267 | 235 | 272 | 301 | 305 | 354 | 361 | 372 | 403 | 376 | 398 | 417 | 453 |
| Operating Profit | 91 | 95 | 77 | 60 | 58 | 64 | 73 | 80 | 77 | 110 | 102 | 114 | 133 |
| OPM % | 25% | 29% | 22% | 17% | 16% | 15% | 17% | 18% | 16% | 23% | 20% | 21% | 23% |
| Other Income | -3 | 6 | 6 | 9 | 12 | 15 | 16 | 14 | 18 | 11 | 10 | 19 | 5 |
| Interest | 2 | 3 | 1 | 2 | 1 | 5 | 2 | 3 | 2 | 2 | 2 | 2 | 3 |
| Depreciation | 9 | 1 | 7 | 7 | 9 | 21 | 11 | 14 | 13 | 14 | 14 | 18 | 22 |
| Profit before tax | 78 | 97 | 75 | 60 | 60 | 53 | 76 | 78 | 79 | 104 | 97 | 114 | 113 |
| Tax % | 24% | 18% | 16% | 23% | 20% | 44% | 21% | 23% | 21% | 21% | 27% | 26% | 26% |
| Net Profit | 59 | 80 | 63 | 46 | 48 | 30 | 60 | 60 | 62 | 83 | 70 | 84 | 83 |
| EPS in Rs | 1.44 | 1.94 | 1.53 | 1.11 | 1.18 | 0.69 | 1.46 | 1.51 | 1.57 | 1.81 | 1.52 | 1.84 | 1.84 |
CAGR Report
Compounded Sales Growth:
| Time Period | Growth Rate |
| 10 Years | 16% |
| 5 Years | 15% |
| 3 Years | 18% |
| TTM | 18% |
Compounded Profit Growth:
| Time Period | Growth Rate |
| 10 Years | 19% |
| 5 Years | 52% |
| 3 Years | 30% |
| TTM | 51% |
Stock Price CAGR:
| Time Period | CAGR |
| 10 Years | 20% |
| 5 Years | 48% |
| 3 Years | 30% |
| 1 Year | 126% |
Return on Equity:
| Time Period | ROE |
| 10 Years | 20% |
| 5 Years | 21% |
| 3 Years | 22% |
| Last Year | 19% |
Marksans Pharma Shareholding Pattern
| Shareholder Type | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | |
| Promoters | 48.60% | 49.00% | 43.85% | 43.85% | 43.85% | 43.85% | 43.85% | |
| FIIs | 4.06% | 4.23% | 15.11% | 14.90% | 15.07% | 15.55% | 15.57% | |
| DIIs | 0.95% | 0.96% | 1.46% | 3.65% | 4.02% | 4.76% | 5.17% | |
| Public | 46.38% | 45.79% | 39.57% | 37.60% | 37.06% | 35.81% | 35.40% | |
| No. of Shareholders | 2,17,743 | 2,13,123 | 1,98,382 | 1,88,447 | 2,07,937 | 2,37,377 | 2,54,699 |
Marksans Pharma Share Price Target 2024-2030 Forecast
| Year | Target |
| 2024 | 228 |
| 2025 | 276 |
| 2026 | 293 |
| 2027 | 334 |
| 2028 | 370 |
| 2029 | 400 |
| 2030 | 450 |
Marksans Pharma Share Price Target 2025
| Months | Target Prices |
| January | 235 |
| February | 240 |
| March | 230 |
| April | 237 |
| May | 244 |
| June | 240 |
| July | 248 |
| August | 255 |
| September | 252 |
| October | 257 |
| November | 268 |
| December | 276 |
Marksans Pharma Share Price Target 2026
| Months | Target Prices |
| January | 280 |
| February | 274 |
| March | 269 |
| April | 271 |
| May | 277 |
| June | 282 |
| July | 285 |
| August | 290 |
| September | 283 |
| October | 284 |
| November | 290 |
| December | 293 |
Marksans Pharma Share Price Target 2027
| Months | Target Prices |
| January | 301 |
| February | 293 |
| March | 287 |
| April | 294 |
| May | 300 |
| June | 306 |
| July | 319 |
| August | 311 |
| September | 320 |
| October | 325 |
| November | 329 |
| December | 334 |
Marksans Pharma Share Price Target 2028
| Months | Target Prices |
| January | 340 |
| February | 331 |
| March | 326 |
| April | 330 |
| May | 337 |
| June | 344 |
| July | 350 |
| August | 357 |
| September | 363 |
| October | 360 |
| November | 364 |
| December | 370 |
Read More:-
Jupiter Wagons Share Price Target
Asian Paints Share Price Target
Marksans Pharma Share Price Target 2029
| Months | Target Prices |
| January | 363 |
| February | 355 |
| March | 350 |
| April | 357 |
| May | 364 |
| June | 370 |
| July | 374 |
| August | 380 |
| September | 384 |
| October | 389 |
| November | 394 |
| December | 400 |
Marksans Pharma Share Price Target 2030
| Months | Target Prices |
| January | 415 |
| February | 402 |
| March | 393 |
| April | 396 |
| May | 405 |
| June | 414 |
| July | 420 |
| August | 429 |
| September | 423 |
| October | 430 |
| November | 440 |
| December | 450 |
Final Words
The Marksans Pharma ltd. company, which was just recently listed on stock exchanges, has performed poorly. Anyway the offer costs are being expanded yet the interest for shares has not been affected in that capacity. The company has been performing its core functions to the satisfaction of customers for a number of years. The company’s core functions are related to the pharmaceutical industry and the manufacturing and retailing of needed medicines, which has created a demand for such businesses.
Stay Updated with the Latest News and Trends
Discover the latest in tech, exams, Sarkari results, and more with our platform. We bring you fresh updates and expert insights to keep you informed and ahead. Join us today and stay on top of the most important developments!